FIELD: medicine, pharmaceutics.
SUBSTANCE: present invention refers to a glucagon-like peptide-1 (GLP-1) analogues presented by general formula I
wherein X represents glycine or glycinamide. The GLP-1 analogue is resistant to the action of dipeptidyl-peptidase IV and thereby has the prolonged half-life in vivo. What is also presented is using the GLP-1 for reducing blood sugar.
EFFECT: preparing the glucagon-like peptide-1.
9 cl, 3 ex, 3 dwg, 1 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| GLP-1 ANALOGUE DERIVATIVE OR ITS PHARMACEUTICALLY ACCEPTABLE SALTS AND THEREOF APPLICATION | 2010 |
|
RU2565536C2 |
| EXENATIDE ANALOGUE | 2020 |
|
RU2823623C1 |
| PHARMACEUTICAL COMPOSITIONS | 2014 |
|
RU2690377C2 |
| PEPTIDE COMPOSITIONS | 2014 |
|
RU2725150C2 |
| NOVEL ANALOGUES OF GLUCAGON-LIKE PEPTIDE, COMPOSITION AND METHOD OF USE | 2010 |
|
RU2557301C2 |
| METHOD FOR IMPROVING SIGNAL TRANSFER IN ISLETS OF LANGERHANS IN DIABETES MELLITUS AND IN ITS PROPHYLAXIS | 2001 |
|
RU2261096C2 |
| ACYLATED DERIVATIVE OF GLP-1 | 2019 |
|
RU2773242C2 |
| METHYL(R)-7-[3-AMINO-4-(2,4,5-TRIFLUOROPHENYL)-BUTYRYL]-3-TRIFLUOROMETHYL-5,6,7,8-TETRAHYDRO-IMIDAZO[1,5-a]PYRAZINE-1-CARBOXYLATE SALTS | 2010 |
|
RU2528233C2 |
| PEG-MODIFIED EXENDIN OR EXENDIN ANALOGUE AND ITS COMPOSITIONS AND USE | 2007 |
|
RU2498814C2 |
| HYPOGLYCEMIC AGENT OF PEPTIDE STRUCTURE INHIBITING DIPEPTIDYL PEPTIDASE-4 | 2015 |
|
RU2600810C1 |
